Business
Kymera Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 23
Company also presenting at upcoming investor conferences WATERTOWN, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"Company also presenting at upcoming investor conferences\nWATERTOWN, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, will report fourth quarter and full year 2022 financial results on February 23, 2023, and will host a conference call at 8:30 a.m. ET that day. Kymera Therapeutics also announced the Company’s management team will participate in fireside chats and industry panels at the following upcoming investor events: Guggenheim Oncology Conference in New York City, NY on February 8, 2023, at 10:10 a.m. ET BMO Virtual Biopharma Spotlight Series on February 10, 2023, at 10:00 a.m. ETSVB Securities Virtual Global Biopharma Conference on February 14, 2023, at 10:00 a.m. ETWells Fargo Virtual Targeted Protein Degradation Summit on February 21, 2023, at 9:00 a.m. ET To access the February 23 conference call via phone, please dial 1-833-630-2127 (U.S.) or 1-412-317-1846 (International) and ask to join the Kymera Therapeutics call. Live webcasts of the Company’s conference call and presentations at upcoming investor events will be available under the “Events and Presentations” section of the Investors page on the Company’s website at www.kymeratx.com. About Kymera Therapeutics Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule programs designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most promising targets and provide patients with more effective treatments. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, and the MDM2 oncoprotein, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce...